Form 8-K - Current report:
SEC Accession No. 0001372514-26-000048
Filing Date
2026-05-08
Accepted
2026-05-08 07:07:40
Documents
13
Period of Report
2026-05-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kprx-20260508.htm   iXBRL 8-K 26003
2 EX-99.1 ex991-pressreleasemarch312.htm EX-99.1 91615
6 KIORA LOGO kprx-20260508_g1.jpg GRAPHIC 348944
  Complete submission text file 0001372514-26-000048.txt   1084443

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kprx-20260508.xsd EX-101.SCH 1800
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kprx-20260508_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kprx-20260508_pre.xml EX-101.PRE 13058
16 EXTRACTED XBRL INSTANCE DOCUMENT kprx-20260508_htm.xml XML 2809
Mailing Address 169 SAXONY RD. SUITE 212 ENCINITAS CA 92024
Business Address 169 SAXONY RD. SUITE 212 ENCINITAS CA 92024 858-224-9600
KIORA PHARMACEUTICALS INC (Filer) CIK: 0001372514 (see all company filings)

EIN.: 980443284 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36672 | Film No.: 26956021
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)